Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.

Marlene L DurandTherese M KittYi SongFrancisco M Marty

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)

This post hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunocompromised or diabetic) with invasive fungal sinusitis (88% mucormycetes, Aspergillus) who received isavuconazole as primary (n = 33) or salvage (n = 17) therapy for a median of 82 days (range, 2-882). Overall survival was 82% at day 42 and 70% at day 84.

Keyphrases

phase iii
end stage renal disease
ejection fraction
open label
clinical trial
newly diagnosed
chronic kidney disease
type diabetes
cell wall
peritoneal dialysis
intensive care unit
patient reported outcomes
phase ii